{
    "clinical_study": {
        "@rank": "80628", 
        "biospec_descr": {
            "textblock": "-  The problem with the existing pre-clinical testing technology\n\n             1. Efficacy evaluation using existing cell lines\n\n             2. Existing preclinical animal models (The tumors produced by the cancer cells\n                subcutaneously injected into immunodeficient mice)\n\n        -  The solution plan\n\n             1. The development of patient-specific personalized cell library\n\n             2. The development of stereotactic(orthotopic) personalized animal models with the\n                patient-derived cell lines derived from patients"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "\u25a0 Unmet medical needs for Refractory cancer Conquest\n\n      - Many advanced cancers are still detected Despite remarkable technological advances for the\n      early diagnosis of cancer in the field last 20 years.\n\n      In the type of progressive carcinoma is very high malignancy despite a variety of\n      therapeutic target treatment for refractory cancer.\n\n      The refractory cancer patients who main focus of this research defined as the adult solid\n      tumor patients who have failed standard therapy according to the criteria\n\n      NCCN / ASCO (American Society of imsangam) / KCSG (Study Group for chemotherapy).\n\n      The survival rate of refractory cancer patients are estimated to be 30-40% of the total\n      patients with metastatic solid tumors and these refractory cancers are\n\n      difficult to deal with or control to conventional treatment so shows almost close to 100%\n      mortality.\n\n      Therefore the new development of therapies for conquer of refractory cancer are urgently\n      required.\n\n      \u25a0 Preclinical translational research Unmet Needs of Bio-new drug development for conquer of\n      refractory cancer\n\n      - The stage of preclinical translational research (Translational Research) connects between\n      the early stages of development and clinical trials in the stage drug development.\n\n      The establishment of foundation based on the translational research is very necessary and\n      this must have proven ability to treat refractory cancer.\n\n      The most anti-cancer drugs developed by existing preclinical testing method actually does\n      not show a remarkable effect in many cases in the clinical trials,\n\n      even if showed a remarkable inhibitory cancer effect in animal testing.\n\n      The exact molecular diagnosis to treat targets and paradigm for the development of new drugs\n      at the same time requires for target treatment.\n\n      The tailored cell lines by patients and the proven technology by animal models and unmet\n      need for preclinical translational research is increasing"
        }, 
        "brief_title": "Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Refractory Cancer", 
        "detailed_description": {
            "textblock": "\u25a0 The specimen obtainer in surgery room contact with the manager of Institute Refractory\n      Cancer Research team by calling to Medi-call system(Phone No.system T.9825).\n\n      The specimen obtainer gives the information of speciman to the manager .\n\n      The manager contact to the speciman deleverer and The speciman deleverer transported the\n      specimens safely to the laboratory space.\n\n      The written informed consent form should obtained from the subject prior to the surgery.\n\n      In the case of blood samples, The total 15 ~ 20 \u3396 blood (only once) extracted from the\n      subject and about 10 ~ 15 \u3396 blood is used for the genomic DNA extraction."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The patients who agreed and written consent to participate in this research\n\n          2. The patients who are scheduled for collection such as the patient tissue, pleural\n             fluid, cerebro spinal fluid, blood samples for the purpose of surgery and diagnostics\n\n          3. The patients who diagnosed with cancer as below - GBM, Colon Cancer, Ovarian Cancer,\n             Lung Cancer, Breast Cancer, Brain metastases, Lymphoma, Bone Metastatic Cancer ,\n             Gastric Cancer,  Pancreatic Cancer, Gall bladder Cancer, Prostate Cancer, Kidney\n             Cancer, Bladder cancer, Osteosarcoma,  Soft tissue sarcoma,  Head and neck cancer, \uae30\ud0c0\n             Brain tumor\n\n        Exclusion Criteria:\n\n          -  1) Those who do not agree in writing to participate in research"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The subject diagnosed with cancer(GBM, Colon Cancer, Ovarian Cancer, Lung Cancer, Breast\n        Cancer, Brain metastases, Bone Metastatic Cancer, Lymphoma, Gastric Cancer, Pancreatic\n        Cancer, Gall bladder Cancer, Prostate Cancer, Kidney Cancer, Bladder cancer, Osteosarcoma,\n        Soft tissue sarcoma, Head and neck cancer),and other Brain tumor"
            }
        }, 
        "enrollment": {
            "#text": "1523", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932047", 
            "org_study_id": "2010-04-004"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Gyunggido", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment - Establishment of Personalized Cell Library", 
        "other_outcome": {
            "description": "Using QIAGEN kit: QIAmp DNA mini kit (Cat. No. 51306)\nThe Volume measurement: Using Spectrophotometer (Nanodrop, ND-1000)", 
            "measure": "Genomic DNA Extraction from blood specimen", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "overall_official": {
            "affiliation": "Institutional Refractory Cancer Research", 
            "last_name": "Jueun Kim, Coordinator", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "\u25a0 Target number of subjects (years) GBM : 120 case Colon Cancer : 200 case Gastric Cancer : 345 case Ovarian Cancer : 40 case Lung Cancer : 30 case Breast Cancer : 100 case Brain metastases : 120 case Bone metastases : 50 case Lymphoma : 10 case Pancreatic Cancer : 100 case Gall Bladder cancer  : 20 case Prostate Cancer : 50 case Kidney Cancer : 100 case Bladder Cancer : 200 case Osteosarcoma : 15 case Soft tissue sarcoma : 50 case Head & neck cancer : 30 case Other Brain tumor : 100case\n- Total case : 1680 case", 
            "measure": "The amount of sample size", 
            "safety_issue": "No", 
            "time_frame": "10years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932047"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Do-hyun Nam", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "In the samples of frozen tissue stored at -80 \u00b0 C are processed by the method Frozen Hematoxylin & Eosin Stain.\nThe criteria of evaluation : tumor size, Tumor Area, Tumor Cell Density, Tumor Nucleus Amount, Necrosis.\nThe Results are distincted by Accept, Intermediate, Fail.", 
            "measure": "The size of real tumor portion on obtained tumor specimen", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "10 Years", 
        "verification_date": "August 2013"
    }
}